fbpx

New York Rabbi Who Recovered From Coronavirus Joins Experimental Treatment

[additional-authors]
March 28, 2020
Coronaviruses research, conceptual illustration. Vials of blood in a centrifuge being tested for coronavirus infection.

Among the mysteries of the coronavirus is that some patients suffer and ultimately die from the disease while others experience the symptoms as akin to a mild cold.

Rabbi Daniel Nevins is in the latter category. The dean of the rabbinical school at the Jewish Theological Seminary, Nevins was laid up for a few days earlier this month with a fever and some aches, and then recovered.

Nevins was tested for the coronavirus on March 12 and a week later got back a positive result. A week after that, he was tested again. Friday morning, he got the result: All clear.

Within hours, Nevins was hooked up to a machine at Mount Sinai Hospital in New York to donate blood plasma. In the race to develop effective treatments for the disease, researchers are investigating whether antibodies from the blood of people who have successfully fought off the disease may provide treatment for people who with more serious symptoms.

Earlier this week, the Food and Drug Administration allowed doctors to treat critically ill coronavirus patients with plasma on an experimental basis. Plasma has been shown effective in treating other infectious diseases, like polio, measles and influenza.

“I felt fortunate that my mild case of this illness might turn into a blessing for people who are seriously ill,” Nevins told the Jewish Telegraphic Agency. “The Torah teaches us not to stand idly by the blood of our neighbor. My Midrash [interpretation] is that no, instead lie down in a donor bed and give plasma.”

Mount Sinai was among the first hospitals in the country to figure out how to detect antibodies in the blood of people who had recovered from coronavirus, the New York Times reported. Whether or not those antibodies are effective remains to be seen.

“It’s kind of difficult scientifically to know how valuable it is in any disease until you try,” said David Reich, the president and chief operating officer of Mount Sinai, told the Times. “It’s not exactly a shot in the dark, but it’s not tried and true.”

Did you enjoy this article?
You'll love our roundtable.

Editor's Picks

Latest Articles

Fire Up the Grill for Memorial Day Weekend

There’s nothing like gathering outdoors, firing up the grill and trying some new, delicious dishes. While traditional cookout fare always has its place, there are plenty of ways to mix things up.

Fighting Smart

A new book by Melanie Phillips challenges the conventional wisdom and offers innovative ideas and practical tools to fight the global surge of antisemitism.

A Ray of Zionist Hope on a College Campus

In a world where encampments, boycotts and student government protests of released hostages make headlines, we must focus on students who want to learn, engage and become bridge builders.

The Ultimate Act of Antisemitism

There are currently two pieces of legislation (in addition to joint resolutions) that are aimed toward stripping Israel of American military arms. Every military action Israel takes is under interpretation for legality. That is despite them battling a multi-front attack.

Shavuot, the Source of American Gratitude

Abraham Lincoln established the yearly American practice of finding – amidst our personal and national battles – sources of brightness within them, and being thankful for them.

Can Harvard Confront the Campus Climate It Helped Create?

The administration has acknowledged rising tensions and concerns about antisemitism, yet it has largely avoided addressing how parts of the university’s own intellectual and institutional culture may have contributed to those conditions.

Between Munich and Vietnam

The fear of acting on uncertain threats can itself become distorting when it evolves into a demand for near-perfect certainty before any meaningful response is considered. History rarely grants that luxury.

More news and opinions than at a Shabbat dinner, right in your inbox.